KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer letters"
DOI: 10.1016/j.canlet.2021.10.019
Abstract: Endometrial cancer (EC) often exhibit aberrant activation of PI3K/Akt/mTOR signaling and targeted therapies using mTOR inhibitors showed limited success. The epigenetic modifier, lysine-specific histone demethylase-1A (KDM1A/LSD1) is overexpressed in EC, however, the mechanistic and therapeutic… read more here.
Keywords: cancer; kdm1a inhibition; mtor; mtor inhibitors ... See more keywords